Search results
Results from the WOW.Com Content Network
Atorvastatin synthesis during discovery chemistry. The key step of establishing stereocenters, using of a chiral ester auxiliary approach. The first synthesis of atorvastatin at Parke-Davis that occurred during drug discovery was racemic followed by chiral chromatographic separation of the enantiomers.
The exact mechanism responsible for the possible increased risk of diabetes mellitus associated with statin use is unclear. [105] However, recent findings have indicated the inhibition of HMGCoAR as a key mechanism. [109] Statins are thought to decrease cells' uptake of glucose from the bloodstream in response to the hormone insulin. [105]
Type 2 statins all exist in their active hydroxy-acid forms. Fluvastatin has indole ring structure, while atorvastatin and rosuvastatin have pyrrole and pyrimidine based ring structure respectively. The lipophilic cerivastatin has a pyridine-based ring structure.
Pentagon officials are holding informal discussions about how the Department of Defense would respond if Donald Trump issues orders to deploy active-duty troops domestically and fire large swaths ...
More than 4 million Americans gouged by credit repair companies including Lexington Law and CreditRepair.com will soon collectively receive $1.8 billion in refund checks, the Consumer Financial ...
MPR provides detailed information on a wide range of prescription drugs, including: Indications and Usage: Descriptions of the approved uses for each medication. Dosage and Administration: Guidelines on how to properly administer the drug, including dosage amounts and frequency. Contraindications: Situations where the drug should not be used.
The more you earn, the more you pay. Since 2007, a beneficiary’s Part B monthly premium is based on his or her income. About 8% of Medicare users earn too much to qualify for the standard Part B ...
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]